Changes in urinary albumin levels with dotinurad oral administration in hyperuricemic patients with microalbuminuria: a post hoc analysis.

ABSTRACT:

Background

Albuminuria is an important indicator of kidney damage. It increases the risk of adverse outcomes such as end-stage renal failure and cardiovascular events. Dotinurad, a drug newly developed in Japan, selectively inhibits renal urate transporter 1. This post hoc analysis of a Japanese, multicenter, phase 3 clinical trial (ClinicalTrials.gov identifier, NCT03006445) of dotinurad in patients with hyperuricemia investigated the effects on urinary albumin levels among a subset of patients with microalbuminuria.

Methods

The study endpoint was the change in urine albumin-to-creatinine ratio (UACR) from baseline at Weeks 34 and 58. Subgroup analyses by patient background and clinical characteristics assessed potential correlations with the change in UACR.

Results

SUBMITTER: Takahashi T 

PROVIDER: S-EPMC12464093 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature